| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Building a more resilient cancer healthcare system
|
The Lancet Oncology,
|
|
|
21 |
8 |
p. 999
|
artikel
|
| 2 |
Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer
|
Kikuchi, Eiji
|
|
|
21 |
8 |
p. 1005-1006
|
artikel
|
| 3 |
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
|
Apolo, Andrea B
|
|
|
21 |
8 |
p. 1099-1109
|
artikel
|
| 4 |
Cancer care in the Commonwealth Caribbean in COVID times
|
Andall-Brereton, Glennis
|
|
|
21 |
8 |
p. 1007-1009
|
artikel
|
| 5 |
Cancer diagnostic delay in the COVID-19 era: what happens next?
|
Hamilton, William
|
|
|
21 |
8 |
p. 1000-1002
|
artikel
|
| 6 |
Carcinogenicity of some aromatic amines and related compounds
|
|
|
|
21 |
8 |
p. 1017-1018
|
artikel
|
| 7 |
Clinical development of immuno-oncology in China
|
Wu, Da-Wei
|
|
|
21 |
8 |
p. 1013-1016
|
artikel
|
| 8 |
Correction to Lancet Oncol 2019; 20: 1556–65
|
|
|
|
21 |
8 |
p. e372
|
artikel
|
| 9 |
Correction to Lancet Oncol 2020; 21: 947–56
|
|
|
|
21 |
8 |
p. e373
|
artikel
|
| 10 |
Correction to Lancet Oncol 2020; 21: 271–82
|
|
|
|
21 |
8 |
p. e372
|
artikel
|
| 11 |
Correction to Lancet Oncol 2019; 20: 1474–76
|
|
|
|
21 |
8 |
p. e372
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: e658
|
|
|
|
21 |
8 |
p. e372
|
artikel
|
| 13 |
Correction to Lancet Oncol 2020; 21: e317–29
|
|
|
|
21 |
8 |
p. e372
|
artikel
|
| 14 |
Correction to Lancet Oncol 2020; 21: e338
|
|
|
|
21 |
8 |
p. e373
|
artikel
|
| 15 |
Correction to Lancet Oncol 2020; 21: e330–36
|
|
|
|
21 |
8 |
p. e372
|
artikel
|
| 16 |
Disruption of cancer care in Canada during COVID-19
|
Chen-See, Sherene
|
|
|
21 |
8 |
p. e374
|
artikel
|
| 17 |
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
|
Sud, Amit
|
|
|
21 |
8 |
p. 1035-1044
|
artikel
|
| 18 |
Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis
|
Ward, Zachary J
|
|
|
21 |
8 |
p. 1077-1088
|
artikel
|
| 19 |
100 European core quality standards for cancer care and research centres
|
Oberst, Simon
|
|
|
21 |
8 |
p. 1009-1011
|
artikel
|
| 20 |
Expanding access to radiotherapy in sub-Saharan Africa
|
Barksby, Rebecca
|
|
|
21 |
8 |
p. 1019
|
artikel
|
| 21 |
First case of osteosarcoma in a dinosaur: a multimodal diagnosis
|
Ekhtiari, Seper
|
|
|
21 |
8 |
p. 1021-1022
|
artikel
|
| 22 |
Hereditary diffuse gastric cancer: updated clinical practice guidelines
|
Blair, Vanessa R
|
|
|
21 |
8 |
p. e386-e397
|
artikel
|
| 23 |
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
|
Johnson, Douglas B
|
|
|
21 |
8 |
p. e398-e404
|
artikel
|
| 24 |
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma
|
Gervaso, Lorenzo
|
|
|
21 |
8 |
p. e370
|
artikel
|
| 25 |
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma – Authors' reply
|
Abou-Alfa, Ghassan K
|
|
|
21 |
8 |
p. e371
|
artikel
|
| 26 |
Knowledge gaps in oncoplastic breast surgery
|
Weber, Walter P
|
|
|
21 |
8 |
p. e375-e385
|
artikel
|
| 27 |
Lenvatinib and pembrolizumab in advanced gastric cancer
|
Cascinu, Stefano
|
|
|
21 |
8 |
p. 1004-1005
|
artikel
|
| 28 |
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
|
Kawazoe, Akihito
|
|
|
21 |
8 |
p. 1057-1065
|
artikel
|
| 29 |
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
|
Catenacci, Daniel V T
|
|
|
21 |
8 |
p. 1066-1076
|
artikel
|
| 30 |
Organisations for patients with cancer feel the brunt of COVID-19 pandemic
|
Nelson, Roxanne
|
|
|
21 |
8 |
p. 1020
|
artikel
|
| 31 |
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial
|
Weiss, Aaron R
|
|
|
21 |
8 |
p. 1110-1122
|
artikel
|
| 32 |
Should we worry about residual disease after mastectomy?
|
Kaidar-Person, Orit
|
|
|
21 |
8 |
p. 1011-1013
|
artikel
|
| 33 |
Skull base lymphoma with panhypopituitarism
|
Rios, Marvin
|
|
|
21 |
8 |
p. e405
|
artikel
|
| 34 |
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
|
Kang, Yoon-Koo
|
|
|
21 |
8 |
p. 1045-1056
|
artikel
|
| 35 |
TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?
|
Samalin, Emmanuelle
|
|
|
21 |
8 |
p. 1002-1003
|
artikel
|
| 36 |
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|
Maringe, Camille
|
|
|
21 |
8 |
p. 1023-1034
|
artikel
|
| 37 |
The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis
|
Ward, Zachary J
|
|
|
21 |
8 |
p. 1089-1098
|
artikel
|
Tijdschrift beschrijving